- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02059850
NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
A Study to Determine the Feasibility of Treating Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Using Autologous NY-ESO-1 Specific CD8+ T Cells With Cyclophosphamide Pre-conditioning But Without the Use of IL-2
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To confirm the safety and efficacy of cancer-testis antigen (NY-ESO-1) specific T cells (autologous NY-ESO-1-specific cluster of differentiation [CD]8-positive T lymphocytes) in patients with advanced synovial sarcoma and myxoid/round cell liposarcoma following conditioning with high dose cyclophosphamide.
SECONDARY OBJECTIVES:
I. To confirm the persistence of NY-ESO-1 tetramer positive cells in the peripheral blood at 10 weeks after T cell infusion for synovial sarcoma and myxoid/round cell liposarcoma patients receiving NY-ESO-1 specific T cells following cyclophosphamide conditioning but not post-infusion interleukin (IL)-2.
OUTLINE:
Patients receive cyclophosphamide intravenously (IV) on days -3 and -2 and NY-ESO-1 specific T cells IV over 60 minutes on day 0. Patients may receive additional infusions at the discretion of the Principal Investigator (PI).
After completion of study treatment, patients are followed up for up to 12 weeks.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
INCLUSION CRITERIA FOR SCREENING:
- Medical history including histopathological documentation of sarcoma
- Informed consent and Health Insurance Portability and Accountability Act (HIPAA) signing
CRITERIA FOR LEUKAPHERESIS:
- NY-ESO-1 expression in tumor by immunohistochemistry (IHC) is not required prior to screening consent; however, patients must have NY-ESO-1 expression to proceed with the leukapheresis; additionally patients must also meet the following criteria to proceed with leukapheresis (any exceptions to this will require prior approval by the Apheresis director and Principal Investigator):
- Physical exam and Karnofsky performance status
- Laboratory evaluation:
- Complete blood count (CBC), differential and platelet count
- Basic metabolic and hepatic function panels
- Puget Sound Blood Center Recipient Donor Battery Panel
- Pregnancy test for females of child-bearing potential
- Pulse > 45 and < 120
- Weight >= 45 kg
- Temperature =< 38 Celsius (C) (=< 100.4 Fahrenheit [F])
- White blood cell (WBC) >= 2,000
- Hematocrit (HCT) >= 30%
- Platelets >= 75,000
- Research blood including 40 mL of blood in a heparinized tube for peripheral blood mononuclear cell (PBMC) collection and 10 mL of blood for serum collection (generally in a red top tube) within 30 days of leukapheresis collection
INCLUSION CRITERIA FOR TREATMENT:
- A diagnosis of synovial sarcoma or myxoid/round cell liposarcoma
- Patients must have "advanced disease"; usually, this will mean metastatic disease; this may also be multiply recurrent disease or locally advanced disease; locally advanced disease is defined for this study as disease where a mutilating surgery is required and the patient is more likely than not to die of their disease despite an aggressive operation; patients with metastatic disease that has been resected or radiated are allowed to participate; Response Evaluation Criteria in Solid Tumors (RECIST) evaluable disease is not necessary for participation
- NY-ESO-1 positive by IHC (for this study, even a small level of positivity is acceptable); for patients with < 5% NY-ESO-1 by IHC positivity, the level of staining should be discussed with the patient and they should be informed that this will likely effect the efficacy of the therapy; this conversation must be documented in the patient's medical chart
- Human leukocyte antigen (HLA)-A0201 or HLA-A2402
- Zubrod performance status of '0-1'
- All patients must have an electrocardiogram (ECG) within 2 weeks of starting conditioning
- All patients must have a stress test within 6 months of starting treatment showing no evidence of cardiac ischemia
- All patients must have an echo or multi gated acquisition scan (MUGA) scan showing ejection fraction (EF) > 50% and normal troponin and creatine kinase (CK) myoglobin binding (MB) (echo may be done at the time of stress test as a stress echo); within 6 months of starting treatment; however if the patient has received cardiotoxic chemotherapy such as Adriamycin, they must have had an echo or MUGA scan since completing this treatment
- If there is a patient with an NY-ESO-1 expressing soft tissue sarcoma who would be otherwise eligible for the trial, which is either not synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCL) or there is controversy about the diagnosis, eligibility will be decided by the PI
- Patients must have NY-ESO-1 specific cells already produced or in production; these cells may be either in the process of their final expansion (for fresh infusion) or expanded and frozen at the time of enrollment
Exclusion Criteria:
- Patients for whom we are unable to generate NY-ESO-1 specific cells
- Pregnant women, nursing women, and men and women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within two weeks prior to study entry
- Serum creatinine > 1.6 mg/dL or glomerular filtration rate < 50
- Serum glutamic oxaloacetic transaminase (SGOT) > 150 IU or > 3 x upper limit of normal
- Bilirubin > 1.6 mg/dL
- Prothrombin time > 1.5 x control
- Active symptomatic congestive heart failure
- Clinically significant hypotension (systolic blood pressure [SBP] < 80 mm HG or symptomatic)
- Newly diagnosed cardiac arrhythmia; patients with an arrhythmia that has been stable for at least 6 months will be allowed to participate
- Known untreated central nervous system (CNS) metastasis; patients with CNS metastasis will be allowed on study once treated
- Patients with active systemic infections requiring antibiotics or chronic maintenance/suppressive therapy; once the infection in question has resolved and patient is off antimicrobial treatment, patients may participate
- Systemic anticancer treatments (including chemotherapy and biologics) less than 3 weeks prior to T cell therapy; locally directed therapy (e.g. radiation) 2 weeks prior to cell infusion
- Known clinically significant autoimmune disorders requiring systemic immunosuppression for control
- Patients who are known to be human immunodeficiency virus (HIV) positive are not eligible for this study
- Current treatment with steroids
- Known infection with hepatitis B virus (HBV) and hepatitis C virus (HCV); (if a patient was not tested at the time of their leukapheresis, they must be tested prior to receiving T cell infusion; if testing was done for leukapheresis, this is adequate and does not need to be repeated)
- Patients with a known history of proven myocarditis, pericarditis, and/ or endocarditis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (cyclophosphamide, NY-ESO-1 specific T cells)
Patients receive cyclophosphamide IV on days -3 and -2 and NY-ESO-1 specific T cells IV over 60 minutes on day 0. Patients may receive additional infusions at the discretion of the PI.
|
Correlative studies
Given IV
Given IV
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of grade III or greater toxicity graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0
Time Frame: Up to 10 weeks
|
The type and grade of toxicities noted during therapy will be summarized for each dose level.
All adverse events noted by the investigator will be tabulated according to the affected body system.
Descriptive statistics will be used to summarize changes from baseline in clinical laboratory parameters.
|
Up to 10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Persistence of tetramer positive T cells
Time Frame: At 4 weeks
|
The standard deviation and variance will be determined.
|
At 4 weeks
|
Persistence of tetramer positive T cells
Time Frame: At 10 weeks
|
The standard deviation and variance will be determined.
|
At 10 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Seth Pollack, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Connective Tissue
- Neoplasms, Adipose Tissue
- Sarcoma
- Liposarcoma
- Liposarcoma, Myxoid
- Sarcoma, Synovial
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
Other Study ID Numbers
- 2720.00 (Other Identifier: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium)
- P30CA015704 (U.S. NIH Grant/Contract)
- K23CA175167 (NIH)
- NCI-2013-02464 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myxoid/Round Cell Liposarcoma
-
GlaxoSmithKlineCompleted
-
Johnson & Johnson Pharmaceutical Research & Development...PharmaMarCompletedLiposarcoma,MyxoidFrance, United States, Germany
-
Mario Negri Institute for Pharmacological ResearchFondazione IRCCS Istituto Nazionale dei Tumori, Milano; Humanitas Hospital,...RecruitingLiposarcoma, Myxoid | Liposarcoma, Dedifferentiated | Liposarcoma, Round CellItaly
-
GlaxoSmithKlineTerminatedNeoplasmsUnited States, Germany, Netherlands, Canada, Australia, Sweden
-
GlaxoSmithKlineActive, not recruitingNeoplasmsUnited States, Netherlands, Canada, United Kingdom
-
M.D. Anderson Cancer CenterSuspendedMyxoid/Round Cell Liposarcoma | Synovial SarcomaUnited States
-
Fred Hutchinson Cancer CenterIncyte CorporationActive, not recruitingRefractory Soft Tissue Sarcoma | Metastatic Leiomyosarcoma | Metastatic Synovial Sarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Advanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Advanced Synovial Sarcoma | Metastatic Chondrosarcoma | Advanced Leiomyosarcoma | Metastatic Myxoid... and other conditionsUnited States
-
Immune DesignGenentech, Inc.TerminatedSarcoma | Myxoid/Round Cell Liposarcoma | Liposarcoma | Synovial Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced SarcomaUnited States
-
AdaptimmuneRecruitingMyxoid Liposarcoma | Synovial SarcomaUnited States, United Kingdom, Canada, France, Spain
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Horizon Pharma USA, Inc.TerminatedMyxoid Liposarcoma | Synovial Sarcoma | Round Cell LiposarcomaUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States